Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942853 | 0.87 | CRHR1 (0.63) | CRHR1ALDH1A1KMT2A | |
| SCHEMBL5849016 | 0.85 | HSD11B1 (0.45) | CRHR1EGLN2HSD11B1NPC1TSHR | |
| SCHEMBL1942440 | 0.80 | CRHR1 (0.51) | CRHR1EGLN2NPC1 | |
| SCHEMBL5847908 | 0.77 | CRHR1 (0.64) | CRHR1EGLN2NPC1 | |
| SCHEMBL1944929 | 0.77 | CRHR1 (0.46) | CRHR1EGLN2NPC1ALDH1A1KMT2A | |
| SCHEMBL5847307 | 0.76 | CRHR1 (0.48) | CRHR1EGLN2NPC1 | |
| SCHEMBL1942843 | 0.76 | CRHR1 (0.77) | CRHR1EGLN2 | |
| SCHEMBL6070921 | 0.75 | CRHR1 (0.43) | CRHR1HSD11B1 | |
| SCHEMBL5848053 | 0.75 | CRHR1 (0.49) | CRHR1EGLN2 | |
| SCHEMBL6616932 | 0.73 | CRHR1 (0.49) | CRHR1EGLN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389618-B1 | PYRAZOLO 1,5-A PYRIDINES AND MEDICINES CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7625925-B2 | Pyrazolo[1,5-a]pyridines and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20070249663-A1 | PYRAZOLO[1,5-a]PYRIDINES AND MEDICINES CONTAINING THE SAME | HIBI SHIGEKI | 2007-10-25 | — | — | US | disclosed |
| US-7285666-B2 | Pyrazolo[1,5-a] pyridines and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7151109-B2 | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060217348-A1 | Pyrazolo[1,5-a] pyridines and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7091215-B2 | Pyrazolo[1,5-a]pyridines and medicines containing the same | EISAI CO., LTD. (JP) | 2006-08-15 | — | — | US | disclosed |
| EP-1485384-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | Pharmacia & Upjohn Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040122039-A1 | Pyrazolo[1,5-a]pyridines and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1389618-A1 | PYRAZOLO 1,5-A]PYRIDINES AND MEDICINES CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003078435-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249663-A1 | PYRAZOLO[1,5-a]PYRIDINES AND MEDICINES CONTAINING THE SAME | NR3C1, NR3C2, NR5A2 | CRHR1 186/4885EGLN2 2614/4885HSD11B1 730/4885 |
| US-20040122039-A1 | Pyrazolo[1,5-a]pyridines and medicines containing the same | XDH, NR3C1, NR5A1 | CRHR1 195/4885EGLN2 3282/4885HSD11B1 540/4885 |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | CRHR1, HTR5A, CRH | CRHR1 1/4885EGLN2 1778/4885HSD11B1 1132/4885 |
| US-20060217348-A1 | Pyrazolo[1,5-a] pyridines and medicines containing the same | NR3C1, NR3C2, NR5A2 | CRHR1 186/4885EGLN2 2614/4885HSD11B1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.